Pfizer's Paxlovid only helped seniors avoid hospitalization and death, new NEJM study finds

Usage of Pfizer’s Covid-19 treatment Paxlovid has spiked across the US in recent months, with more than 2 million courses administered during this latest Omicron wave since June, potentially saving many from hospitalization or death.

But a new observational study published in the New England Journal of Medicine on Wednesday evening found that Paxlovid only worked among patients 65 years of age or older, with no evidence of benefit found in younger adults.